BASI Bioanalytical Systems, Inc. gains 34% Dec 19, 2017

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, other North America, the Pacific Rim, Europe, and internationally. It operates in two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services. It also provides in vivo sampling services for the continuous monitoring of chemical changes in life; preclinical and pathology services; product characterization, method development, and validation; bioanalytical testing to measure drug and metabolite concentrations in complex biological matrices; and stability testing to establish and confirm product purity, potency, and shelf life. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana. http://www.priceseries.com/trade/BASI-Bioanalytical-Systems-Inc-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2017111320171219.html